Literature DB >> 16501067

Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior.

Joris H De Maeyer1, Nicolaas H Prins, Jan A J Schuurkes, Romain A Lefebvre.   

Abstract

Quantification of different levels of 5-hydroxytryptamine4 (5-HT4) receptor agonism expression across animal species as well as across organs within the same animal species offers substantial potential for the separation of desired gastrointestinal versus undesired cardiac pharmacological activity of compounds in development. Since a detailed investigation of such properties is lacking to date, we set out to quantify gastric and cardiac effects of 5-HT4 receptor ligands in the pig, a model considered to be representative for the human situation. An in vitro test was developed to study the potentiating effect of 5-HT, prucalopride, tegaserod, R149402 (4-amino-5-chloro-2,2-dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4ylmethyl]-amide), and R199715 (4-amino-5-chloro-2,3-dihydro-benzofuran-7-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4ylmethyl]-amide) on electrically induced cholinergic contractions in longitudinal muscle strips of the proximal stomach. The results were compared with inotropic and chronotropic effects of these compounds in the electrically paced left atrium and spontaneously beating right atrium, respectively. To quantify the observed tissue-dependent responses, a nonlinear mixed-effects model based on the operational model of agonism was developed and successfully fitted to the data. The model quantified the tissue-dependent partial agonism of the selective 5-HT4 receptor agonists prucalopride, R149402, and R199715, whereas tegaserod and 5-HT were equiefficacious. The model was further extended to incorporate the responses to prucalopride in the presence of the 5-HT4 receptor antagonist GR113808 ([1-[2-[(methylsulphonyl)amino]ethyl]-4-piperidinyl-]methyl 1-methyl-1H-indole-3-carboxylate). The results indicate that these interactions do not follow a simple competitive pattern and that they differ between stomach and left atrium.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16501067     DOI: 10.1124/jpet.106.101329

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  New treatment options for chronic constipation: mechanisms, efficacy and safety.

Authors:  Michael Camilleri
Journal:  Can J Gastroenterol       Date:  2011-10       Impact factor: 3.522

2.  Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach.

Authors:  J H De Maeyer; J A J Schuurkes; R A Lefebvre
Journal:  Br J Pharmacol       Date:  2009-01-13       Impact factor: 8.739

3.  The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.

Authors:  J A M Smith; D T Beattie; D Marquess; J P Shaw; R G Vickery; P P A Humphrey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-16       Impact factor: 3.000

4.  Cardiovascular effects of cisapride and prucalopride on human 5-HT4 receptors in transgenic mice.

Authors:  Nicolas Keller; Stefan Dhein; Joachim Neumann; Ulrich Gergs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-09       Impact factor: 3.000

5.  A comparison of the pharmacological properties of guinea-pig and human recombinant 5-HT4 receptors.

Authors:  R G Vickery; N Mai; E Kaufman; D T Beattie; T Pulido-Rios; M O'Keefe; P P A Humphrey; J A M Smith
Journal:  Br J Pharmacol       Date:  2007-02-12       Impact factor: 8.739

Review 6.  Behavioural and new pharmacological treatments for constipation: getting the balance right.

Authors:  Michael Camilleri; Adil E Bharucha
Journal:  Gut       Date:  2010-09       Impact factor: 23.059

7.  Which phosphodiesterase can decrease cardiac effects of 5-HT4 receptor activation in transgenic mice?

Authors:  Joachim Neumann; Benedikt Käufler; Ulrich Gergs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-24       Impact factor: 3.000

8.  Predominant mucosal expression of 5-HT₄(+h) receptor splice variants in pig stomach and colon.

Authors:  Evelien K V Priem; Joris H De Maeyer; Mado Vandewoestyne; Dieter Deforce; Romain A Lefebvre
Journal:  World J Gastroenterol       Date:  2013-06-28       Impact factor: 5.742

Review 9.  Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.

Authors:  J Tack; M Camilleri; L Chang; W D Chey; J J Galligan; B E Lacy; S Müller-Lissner; E M M Quigley; J Schuurkes; J H De Maeyer; V Stanghellini
Journal:  Aliment Pharmacol Ther       Date:  2012-02-22       Impact factor: 8.171

10.  Effect of prucalopride on the pharmacokinetics of oral contraceptives in healthy women.

Authors:  Vera Van de Velde; Lieve Vandeplassche; Mieke Hoppenbrouwers; Mark Boterman; Jannie Ausma
Journal:  Drugs R D       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.